Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease
Abstract
:Simple Summary
Abstract
1. Introduction
2. Overview on EBV Biology
3. Overview on the PD-1/PD-L1 Axis and Its Relation to EBV in Lymphomas
4. Clinicopathological Features of IVNKTL
5. Molecular Features and Pathogenesis of IVNKTL
6. Differential Diagnoses of IVNKTL
6.1. ENKTL, ANKL, and EBV-Positive Nodal T/NK Lymphoma
6.2. Extranodal NK/T-Cell Lymphoma (ENKTL)
6.2.1. General Features and Clinical Manifestations
6.2.2. Histology
6.2.3. Immunophenotypic Features
6.2.4. Genetic Features
6.2.5. Treatment
6.3. EBV-Positive Nodal T/NK-Cell Lymphoma
6.3.1. General Features and Clinical Manifestations
6.3.2. Histology and Immunophenotypic Features
6.3.3. Genetic Features
6.4. Aggressive NK-Cell Leukemia (ANKL)
6.4.1. General Features and Clinical Manifestations
6.4.2. Histology and Immunophenotypic Features
6.4.3. Genetic Features
6.4.4. Treatment
7. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Santucci, M.; Pimpinelli, N.; Massi, D.; Kadin, M.E.; Meijer, C.J.L.M.; Muller-Hermelink, H.K.; Paulli, M.; Wechsler, J.; Willemze, R.; Audrig, H.; et al. EORTC cutaneous Lymphoma Task Force. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC cutaneous lymphoma Task Force workshop. Cancer 2003, 97, 610–627. [Google Scholar] [CrossRef] [PubMed]
- Wu, H.; Said, J.W.; Ames, E.D.; Chen, C.; McWorther, V.; Chen, P.; Ghali, V.; Pinkus, G.S. First reported cases of intravascular Large cell lymphoma of the NK cell type. Am. J. Clin. Pathol. 2005, 123, 603–611. [Google Scholar] [CrossRef] [PubMed]
- Kuo, T.-T.; Chen, M.-J.; Kuo, M.-C. Cutaneous intravascular NK-cell lymphoma: Report of a rare variant associated with Ep-stein-Barr virus. Am. J. Surg. Pathol. 2006, 30, 1197–1201. [Google Scholar] [CrossRef]
- Song, D.E.; Lee, M.-W.; Ryu, M.-H.; Kang, D.W.; Kim, S.J.; Huh, J. Intravascular Large Cell Lymphoma of the Natural Killer Cell Type. J. Clin. Oncol. 2007, 25, 1279–1282. [Google Scholar] [CrossRef] [PubMed]
- Nakamichi, N.; Fukuhara, S.; Aozasa, K.; Morii, E. NK-cell intravascular lymphomatosis—A mini-review. Eur. J. Haematol. 2008, 81, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Gleason, B.C.; Brinster, N.K.; Granter, S.R.; Pinkus, G.S.; Lindeman, N.I.; Miller, D.M. Intravascular cytotoxic T-cell lymphoma: A case report and review of the literature. J. Am. Acad. Dermatol. 2008, 58, 290–294. [Google Scholar] [CrossRef]
- Cerroni, L.; Massoni, C.; Kutzner, H.; Mentzel, T.; Umbert, P.; Kerl, H. Intravascular large T-cell or NK-cell lymphoma: A rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein-Barr virus infection. Am. J. Surg. Pathol. 2008, 32, 891–898. [Google Scholar] [CrossRef]
- Wu, C.; Liao, J.; Hsieh, P.; Hwang, Y.; Lin, S. Cutaneous Intravascular Natural Killer-cell Lymphoma: A Rare Case and Review of the Literature. Acta Derm. Venereol. 2011, 91, 472–473. [Google Scholar] [CrossRef] [Green Version]
- Yanning, X.; Chen, H.; Si, H.; Liu, Y.; Min, Z. Cutaneous intravascular NK-cell lymphoma. Eur. J. Dermatol. 2013, 23, 252–253. [Google Scholar] [CrossRef]
- Liu, Y.; Zhang, W.; An, J.; Li, H.; Liu, S. Cutaneous Intravascular Natural Killer–Cell Lymphoma. Am. J. Clin. Pathol. 2014, 142, 243–247. [Google Scholar] [CrossRef]
- Bi, Y.; Huo, Z.; Liang, Z.; Yunxiao, M.Y.; Jia, C.; Shi, X.; Song, L.; Luo, Y.; Ling, Q.; Liu, T. Intravascular NK-cell lymphoma: A case report and review of the literature. Diagn. Pathol. 2015, 10, 84. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, L.; Chen, S.; Ma, H.; Shi, D.; Huang, C.; Lu, C.; Gao, T.; Wang, G. Intravascular NK/T-cell lymphoma: A report of five cases with cutaneous manifestation from China. J. Cutan. Pathol. 2015, 42, 610–617. [Google Scholar] [CrossRef] [PubMed]
- Sharma, T.L.; Yeaney, G.A.; Soltanzadeh, P.; Li, Y.; Cotta, C.V. Intravascular T-cell lymphoma: A rare, poorly characterized entity with cytotoxic phenotype. Neuropathology 2017, 37, 365–370. [Google Scholar] [CrossRef]
- Yan, J.; Zhang, F.; Luo, D.; Yao, S.; Chen, Y.; Xu, F.; Luo, X.; He, J.; Liu, Y. Intravascular NK/T-cell lymphoma: A series of four cases. Int. J. Clin. Exp. Pathol. 2017, 10, 9541–9550. [Google Scholar] [PubMed]
- Alegría-Landa, V.; Manzarbeitia, F.; Calderón, M.G.S.; Requena, L.; Rodríguez-Pinilla, S.M. Cutaneous intravascular natural killer/T cell lymphoma with peculiar immunophenotype. Histopathology 2017, 71, 994–1002. [Google Scholar] [CrossRef] [PubMed]
- Okonkwo, L.; Jaffe, E.S. Intravascular large cell lymphoma of NK/T-cell type, EBV positive. Blood 2017, 130, 837. [Google Scholar] [CrossRef] [Green Version]
- Elshiekh, M.; Naresh, K.N. A rare case of renal intravascular NK/T-cell lymphoma. Blood 2018, 132, 1354. [Google Scholar] [CrossRef] [Green Version]
- Zanelli, M.; Mengoli, M.C.; Del Sordo, R.; Cagini, A.; De Marco, L.; Simonetti, E.; Martino, G.; Zizzo, M.; Ascani, S. Intravascular NT/T-cell lymphoma, Epstein-Barr virus positive with multiorgan involvement: A clinical dilemma. BMC Cancer 2018, 18, 1115. [Google Scholar] [CrossRef]
- Fujikura, K.; Yamashita, D.; Sakamoto, R.; Ishikawa, T.; Chuang, S.-S.; Itoh, T.; Imai, Y. Intravascular NK/T-cell lymphoma: Clinicopathological and integrated molecular analysis of two cases provides a clue to disease pathogenesis. J. Clin. Pathol. 2019, 72, 642–646. [Google Scholar] [CrossRef]
- Wang, J.; Yang, X.; Song, Z.; You, Y. Cutaneous intravascular NK/T-cell lymphoma. Australas. J. Dermatol. 2019, 61, 61–63. [Google Scholar] [CrossRef]
- Fujikura, K.; Yoshida, M.; Uesaka, K. Transcriptome complexity in intravascular NK/T-cell lymphoma. J. Clin. Pathol. 2020, 73, 671–675. [Google Scholar] [CrossRef] [PubMed]
- WHO Classification of Tumours Editorial Board (Ed.) WHO Classification of Tumours Haematopoietic and Lymphoid Tissues, Revised 4th ed.; IARC: Lyon, France, 2017. [Google Scholar]
- Sánchez-Romero, C.; Bologna-Molina, R.; de Almeida, O.P.; Santos-Silva, A.R.; Prado-Ribeiro, A.C.; Brandão, T.B.; Carlos, R. Extranodal NK/T cell lymphoma, nasal type: An updated overview. Crit. Rev. Oncol. 2021, 159, 103237. [Google Scholar] [CrossRef] [PubMed]
- Huang, Y.; de Leval, L.; Gaulard, P. Molecular underpinning of extranodal NK/T-cell lymphoma. Best Pr. Res. Clin. Haematol. 2013, 26, 57–74. [Google Scholar] [CrossRef] [PubMed]
- Takata, K.; Hong, M.E.; Sitthinamsuwan, P.; Loong, F.; Tan, S.Y.; Liau, J.Y.; Hsieh, P.P.; Ng, S.B.; Yang, S.F.; Pongpruttipan, T.; et al. Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma: A cellular lineage and clinicopathologic study of 60 patients from Asia. Am. J. Surg. Pathol. 2015, 39, 1–12. [Google Scholar] [CrossRef]
- Syrykh, C.; Péricart, S.; Lamaison, C.; Escudié, F.; Brousset, P.; Laurent, C. Epstein–Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features. Cancers 2021, 13, 3315. [Google Scholar] [CrossRef] [PubMed]
- Takada, H.; Imadome, K.I.; Shibayama, H.; Yoshimori, M.; Wang, L.; Saitoh, Y.; Uota, S.; Yamaoka, S.; Koyama, T.; Shimizu, N.; et al. EBV induces persistent NF-kB activation and contributes to survival of EBV-positive neoplastic T-or NK-cells. PLoS ONE 2017, 12, e0174136. [Google Scholar]
- Zanelli, M.; Sanguedolce, F.; Palicelli, A.; Zizzo, M.; Martino, G.; Caprera, C.; Fragliasso, V.; Soriano, A.; Gozzi, F.; Cimino, L.; et al. EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 3). Cancers 2021, 13, 6021. [Google Scholar] [CrossRef]
- Alaggio, R.; Amador, C.; Anagnostopoulos, I.; Ayoma, D.; Attygalle, A.D.; de Oliveira Araujo, I.B.; Borges, A.M.; Boyer, D.; Calaminici, M.; Chadburn, A.; et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022, 36, 1720–1748. [Google Scholar] [CrossRef]
- Taylor, G.S.; Long, H.M.; Brooks, J.M.; Rickinson, A.B.; Hislop, A.D. The Immunology of Epstein-Barr Virus–Induced Disease. Annu. Rev. Immunol. 2015, 33, 787–821. [Google Scholar] [CrossRef]
- Young, L.; Yap, L.-F.; Murray, P.G. Epstein–Barr virus: More than 50 years old and still providing surprises. Nat. Cancer 2016, 16, 789–802. [Google Scholar] [CrossRef]
- Rickinson, A. Co-infections, inflammation and oncogenesis: Future directions for EBV research. Semin. Cancer Biol. 2014, 26, 99–115. [Google Scholar] [CrossRef] [PubMed]
- Price, A.M.; Luftig, M.A. To Be or Not IIb: A Multi-Step Process for Epstein-Barr Virus Latency Establishment and Consequences for B Cell Tumorigenesis. PLOS Pathog. 2015, 11, e1004656. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dojcinov, S.; Fend, F.; Quintanilla-Martinez, L. EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts. Pathogens 2018, 7, 28. [Google Scholar] [CrossRef] [Green Version]
- Fujiwara, S.; Kimura, H. Editorial: Epstein-Barr Virus-Associated T/NK-Cell Lymphoproliferative Diseases. Front. Pediatr. 2019, 7, 285. [Google Scholar] [CrossRef] [PubMed]
- Kim, W.Y.; Montes-Mojarro, I.A.; Fend, F.; Quintanilla-Martinez, L. Epstein-Barr virus-associated T and NK-cell lymphopro-liferative diseases. Front. Pediatr. 2019, 7, 71. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kimura, H.; Fujiwara, S. Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases. Front. Pediatr. 2019, 6, 417. [Google Scholar] [CrossRef]
- Kim, H.; Ko, Y.H. The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma. Life 2022, 12, 73. [Google Scholar] [CrossRef] [PubMed]
- Zanelli, M.; Sanguedolce, F.; Palicelli, A.; Zizzo, M.; Martino, G.; Caprera, C.; Fragliasso, V.; Soriano, A.; Valle, L.; Ricci, S.; et al. EBV-driven lymphoproliferative disorders and lymphomas of the gastrointestinal tract: A spectrum of entities with a common denominator (Part 1). Cancers 2021, 13, 4578. [Google Scholar] [CrossRef]
- Zanelli, M.; Sanguedolce, F.; Palicelli, A.; Zizzo, M.; Martino, G.; Caprera, C.; Fragliasso, V.; Soriano, A.; Valle, L.; Ricci, S.; et al. EBV-driven lymphoproliferative disorders and lymphomas of the gastrointestinal tract: A spectrum of entities with a common denominator (Part 2). Cancers 2021, 13, 4527. [Google Scholar] [CrossRef]
- Patsoukis, N.; Wang, Q.; Strauss, L.; Boussiotis, V.A. Revisiting the PD-1 pathway. Sci. Adv. 2020, 6, eabd2712. [Google Scholar] [CrossRef]
- Lipson, E.J.; Forde, P.M.; Hammers, H.-J.; Emens, L.A.; Taube, J.M.; Topalian, S.L. Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin. Oncol. 2015, 42, 587–600. [Google Scholar] [CrossRef]
- Alsaab, H.O.; Sau, S.; Alzhrani, R.; Tatiparti, K.; Bhise, K.; Kashaw, S.K.; Iyer, A.K. PD-1 and PD-L1 chechpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations and clinical outcome. Front. Pharmacol. 2017, 8, 561. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palicelli, A.; Bonacini, M.; Croci, S.; Magi-Galluzzi, C.; Cañete-Portillo, S.; Chaux, A.; Bisagni, A.; Zanetti, E.; De Biase, D.; Melli, B.; et al. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables. Cells 2021, 10, 3166. [Google Scholar] [CrossRef]
- Ansell, S.M.; Lesokhin, A.M.; Borrello, I.; Halwani, A.; Scott, E.C.; Gutierrez, M.; Schuster, S.J.; Millenson, M.M.; Cattry, D.; Freeman, G.J.; et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. N. Engl. J. Med. 2015, 372, 311–319. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lesokhin, A.M.; Ansell, S.M.; Armand, P.; Scott, E.C.; Halwani, A.; Gutierrez, M.; Millenson, M.M.; Cohen, A.D.; Schuster, S.J.; Lebovic, D.; et al. Nivolumab in patients with repalsed or refractory hematologic malignancy: Preliminary results of a phase Ib study. J. Clin. Oncol. 2016, 34, 2698–2704. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Satou, A.; Nakamura, S. EBV-positive B-cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency. Cancer Med. 2021, 10, 6777–6785. [Google Scholar] [CrossRef]
- Ferreri, A.J.; Dognini, G.P.; Campo, E.; Willemze, R.; Seymour, J.F.; Bairey, O.; Martelli, M.; De Renz, A.O.; Doglioni, C.; Montalban, C.; et al. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of in-travascular lymphoma diagnosed in different geographical regions. Haematologica 2007, 92, 486–492. [Google Scholar] [CrossRef] [Green Version]
- Pastor, W.A.; Aravind, L.; Rao, A. TETonic shift: Biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 2013, 14, 341–356. [Google Scholar] [CrossRef] [Green Version]
- Bi, X.-W.; Wang, H.; Zhang, W.-W.; Wang, J.-H.; Liu, W.-J.; Xia, Z.-J.; Huang, H.-Q.; Jiang, W.-Q.; Zhang, Y.-J.; Wang, L. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lym-phoma. J. Hematol. Oncol. 2016, 9, 3432–3433. [Google Scholar] [CrossRef] [Green Version]
- Scheel, A.H.; Baenfer, G.; Baretton, G.; Dietel, M.; Diezko, R.; Henkel, T.; Heukamp, L.C.; Jasani, B.; Johrens, K.; Kirchner, T.; et al. Interlaboratory concordance of PD- L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018, 72, 449–459. [Google Scholar] [CrossRef]
- Batenchuk, C.; Albitar, M.; Zerba, K.; Sudarsanam, S.; Chizhevsky, V.; Jin, C.; Burns, V. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies. J. Clin. Pathol. 2018, 71, 1078–1083. [Google Scholar] [CrossRef] [PubMed]
- Menguy, S.; Prochazkova-Carlotti, M.; Beylot-Barry, M.; Saltel, F.; Vergier, B.; Merlio, J.-P.; Pham-Ledard, A. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Am. J. Surg. Pathol. 2018, 42, 326–334. [Google Scholar] [CrossRef] [PubMed]
- Mitteldorf, C.; Berisha, A.; Pfaltz, M.C.; Broekaert, S.M.; Schön, M.P.; Kerl, K.; Kempf, W. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma—New Therapeutic Targets. Am. J. Surg. Pathol. 2017, 41, 998–1004. [Google Scholar] [CrossRef] [Green Version]
- Sakakibara, A.; Kohno, K.; E Eladl, A.; Klaisuwan, T.; Ishikawa, E.; Suzuki, Y.; Shimada, S.; Nakaguro, M.; Shimoyama, Y.; Takahara, T.; et al. Immunohistochemical assessment of the diagnostic utility of PD-L1: A preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells. Histopathology 2018, 72, 1156–1163. [Google Scholar] [CrossRef]
- Harrow, J.; Frankish, A.; Gonzalez, J.M.; Tapanari, E.; Diekhans, M.; Kokocinski, F.; Aken, B.L.; Barrell, D.; Zadissa, A.; Searle, S.; et al. GENCODE: The reference human genome annotation for The ENCODE Project. Genome Res. 2012, 22, 1760–1774. [Google Scholar] [CrossRef] [Green Version]
- Lee, Y.; Rio, D.C. Mechanisms and regulation of alternative pre-mRNA splicing. Annu. Rev. Biochem. 2015, 84, 291–323. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Venables, J.P. Aberrant and Alternative Splicing in Cancer. Cancer Res. 2004, 64, 7647–7654. [Google Scholar] [CrossRef] [Green Version]
- Anczuków, O.; Krainer, A.R. Splicing-factor alterations in cancers. RNA 2016, 22, 1285–1301. [Google Scholar] [CrossRef] [Green Version]
- Clemente-González, H.; Porta-Pardo, E.; Godzik, A.; Eyra, E. The functional impact of alternative splicing in cancer. Cell. Rep. 2017, 20, 2215–2226. [Google Scholar] [CrossRef] [Green Version]
- Koedoot, E.; Smid, M.; Foekens, J.A.; Martens, J.W.M.; Le Dévédec, S.E.; Van De Water, B. Co-regulated gene expression of splicing factors as drivers of cancer progression. Sci. Rep. 2019, 9, 5484. [Google Scholar] [CrossRef] [Green Version]
- Escobar-Hoyos, L.; Knorr, K.; Abdel-Wahab, O. Aberrant RNA Splicing in Cancer. Annu. Rev. Cancer Biol. 2019, 3, 167–185. [Google Scholar] [CrossRef] [PubMed]
- Rodrigues-Peres, R.M.; de S Carvalho, B.; Anurag, M.; Lei, J.T.; Conz, L.; Goncalves, R.; Filho, C.C.; Ramalho, S.; de Paiva, G.R.; Derchain, S.F.M.; et al. Copy number alterations associated with clinical features in an underrepresented population with breast cancer. Mol. Genet. Genomic.Med. 2019, 7, e00750. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Foy, A.; McMullin, M.F. Somatic SF3B1 mutations in myelodysplastic syndrome with ring sideroblasts and chronic lympho-cytic leukaemia. J. Clin. Pathol. 2019, 72, 778–782. [Google Scholar] [CrossRef] [PubMed]
- Kim, T.M.; Lee, S.Y.; Jeon, Y.K.; Ryoo, B.Y.; Cho, G.J.; Hong, Y.S.; Kim, H.J.; Kim, S.Y.; Kim, C.S.; Kim, S.; et al. Lymphoma Subcommittee of the Korean Cancer Study Group. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: A national survey of the Korean Cancer Study Group. Ann. Oncol. 2008, 19, 1477–1484. [Google Scholar] [CrossRef]
- Au, W.-Y.; Weisenburger, D.D.; Intragumtornchai, T.; Nakamura, S.; Kim, W.-S.; Sng, I.; Vose, J.; Armitage, J.O.; Liang, R. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009, 113, 3931–3937. [Google Scholar] [CrossRef] [Green Version]
- Li, N.; Jiang, M.; Wu, W.-C.; Wei, W.-W.; Zou, L.-Q. How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome. Front. Oncol. 2021, 11, 704962. [Google Scholar] [CrossRef]
- Ling, Y.-H.; Zhu, C.-M.; Wen, S.-H.; Luo, R.-Z.; Li, P.; Cao, Y.; Rao, H.-L.; Lin, S.-X.; Cai, M.-Y. Pseudoepitheliomatous hyperplasia mimicking invasive squamous cell carcinoma in extranodal natural killer/T-cell lymphoma: A report of 34 cases. Histopathology 2015, 67, 404–409. [Google Scholar] [CrossRef]
- Pongpruttipan, T.; Sukpanichnant, S.; Assanasen, T.; Wannakrairot, P.; Boonsakan, P.; Kanoksil, W.; Kayasut, K.; Mitarnun, W.; Khuhapinant, A.; Bunworasate, U.; et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: A comprehensive clinicopathologic and phenotypic study. Am. J. Surg. Pathol. 2012, 6, 481–499. [Google Scholar] [CrossRef]
- Huang, Y.; Chen, S.; Wei, R.; Guo, X.; Yang, X.; Cao, Q.; Yang, Y.; Yun, J. CD20-positive extranodal NK/T cell lymphoma: Clinicopathologic and prognostic features. Virchows Arch. 2020, 477, 873–883. [Google Scholar] [CrossRef]
- Jo, J.-C.; Kim, M.; Choi, Y.; Kim, H.-J.; Kim, J.E.; Chae, S.W.; Kim, H.; Cha, H.J. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. Ann. Hematol. 2016, 96, 25–31. [Google Scholar] [CrossRef]
- Tse, E.; Kwong, Y.-L. Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies. Cancers 2022, 14, 597. [Google Scholar] [CrossRef]
- Xiong, J.; Zhao, W.-L. Advances in multiple omics of natural-killer/T cell lymphoma. J. Hematol. Oncol. 2018, 11, 134. [Google Scholar] [CrossRef]
- Coppo, P.; Gouilleux-Gruart, V.; Huang, Y.; Bouhlal, H.; Bouamar, H.; Bouchet, S.; Perrot, C.; Vieillard, V.; Dartigues, P.; Gaulard, P.; et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia 2009, 23, 1667–1678. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, Y.; De Reyniès, A.; de Leval, L.; Ghazi, B.; Martin-Garcia, N.; Travert, M.; Bosq, J.; Brière, J.; Petit, B.; Thomas, E.; et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 2010, 115, 1226–1237. [Google Scholar] [CrossRef] [PubMed]
- Nairismägi, M.; Gerritsen, M.E.; Li, Z.M.; Wijaya, G.C.; Chia, B.K.H.; Laurensia, Y.; Lim, J.Q.; Yeoh, K.W.; Yao, X.S.; Pang, W.L.; et al. Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. Leukemia 2018, 32, 1147–1156. [Google Scholar] [CrossRef] [PubMed]
- Dong, G.; Li, Y.; Lee, L.; Liu, X.; Shi, Y.; Liu, X.; Bouska, A.; Gong, Q.; Kong, L.; Wang, J.; et al. Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1. Haematologica 2020, 106, 2427–2438. [Google Scholar] [CrossRef]
- Kwong, Y.L.; Kim, W.S.; Lim, S.T.; Kim, S.J.; Tang, T.; Tse, E.; Leung, A.Y.; Chim, C.S. SMILE for natural killer/T-cell lymphoma: Analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012, 120, 2973–2980. [Google Scholar] [CrossRef] [Green Version]
- Sun, K.-H.; Wong, Y.-T.; Cheung, K.-M.; Yuen, C.; Chan, Y.-T.; Lai, W.-Y.; Chao, C.; Fan, W.-S.; Chow, Y.-K.; Law, M.-F.; et al. Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine. Diagnostics 2022, 12, 409. [Google Scholar] [CrossRef]
- Tse, E.; Zhao, W.-L.; Xiong, J.; Kwong, Y.-L. How we treat NK/T-cell lymphomas. J. Hematol. Oncol. 2022, 15, 74. [Google Scholar] [CrossRef]
- Kwong, Y.-L.; Chan, T.S.Y.; Tan, D.; Kim, S.J.; Poon, L.-M.; Mow, B.; Khong, P.-L.; Loong, F.; Au-Yeung, R.; Iqbal, J.; et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood 2017, 129, 2437–2442. [Google Scholar] [CrossRef] [Green Version]
- Kim, S.J.; Yoon, D.H.; Kim, J.S.; Kang, H.J.; Lee, H.W.; Eom, H.S.; Hong, J.Y.; Cho, J.; Ko, Y.H.; Huh, J. Efficay of Brentuximab Vedotin in relapsed or refractory high-CD30-expressing non-Hodgkin lymphomas: Results of a multicenter, open-labeled Phase II trial. Cancer Res. Treat. 2020, 52, 374–387. [Google Scholar] [CrossRef] [PubMed]
- Campo, E.; Jaffe, E.S.; Cook, J.R.; Quintanilla-Martinez, L.; Swerdlow, S.H.; Anderson, K.C.; Brousset, P.; Cerroni, L.; de Leval, L.; Dirnhofer, S.; et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee. Blood 2022, 140, 1229–1253. [Google Scholar] [CrossRef] [PubMed]
- Feldman, A.L.; Laurent, C.; Narbaitz, M.; Nakamura, S.; Chan, W.C.; de Leval, L.; Gaulard, P. Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas. Virchows Arch. 2022, 1–15. [Google Scholar] [CrossRef] [PubMed]
- Quintanilla-Martinez, L.; Swerdlow, S.H.; Tousseyn, T.; Barrionuevo, C.; Nakamura, S.; Jaffe, E.S. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2022, 1–18. [Google Scholar] [CrossRef]
- Jeon, Y.K.; Kim, J.-H.; Sung, J.-Y.; Han, J.H.; Ko, Y.-H. Epstein-Barr virus–positive nodal T/NK-cell lymphoma: An analysis of 15 cases with distinct clinicopathological features. Hum. Pathol. 2015, 46, 981–990. [Google Scholar] [CrossRef]
- Kato, S.; Asano, N.; Miyata-Takata, T.; Takata, K.; Elsayed, A.A.; Satou, A.; Takahashi, E.; Kinoshita, T.; Nakamura, S. T-cell receptor (TCR) phenotype of nodal Epstein-Barr virus (EBV)-positive cytotoxic T-cell lymphoma (CTL): A clinicopathologic study of 39 cases. Am. J. Surg. Pathol. 2015, 39, 462–471. [Google Scholar] [CrossRef]
- Takahashi, E.; Asano, N.; Li, C.; Tanaka, T.; Shimada, K.; Shimada, S.; Yoshino, T.; Kojima, M.; Hara, K.; Eimoto, T.; et al. Nodal T/NK-cell lymphoma of nasal type: A clinicopathological study of six cases. Histopathology 2008, 52, 585–596. [Google Scholar] [CrossRef]
- Wai, C.M.M.; Chen, S.; Phyu, T.; Fan, S.; Leong, S.M.; Zheng, W.; Low, L.C.Y.; Choo, S.N.; Lee, C.K.; Chung, T.H.; et al. Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica 2022, 107, 1864–1879. [Google Scholar] [CrossRef]
- Suzuki, R.; Suzumiya, J.; Nakamura, S.; Aoki, S.; Notoya, A.; Ozaki, S.; Gondo, H.; Hino, N.; Mori, H.; Sugimori, H.; et al. Aggressive natural killer-cell leukemia revisited: Large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004, 18, 763–770. [Google Scholar] [CrossRef] [Green Version]
- Tang, Y.-T.; Wang, D.; Luo, H.; Xiao, M.; Zhou, H.-S.; Liu, D.; Ling, S.-P.; Wang, N.; Hu, X.-L.; Luo, Y.; et al. Aggressive NK-cell leukemia: Clinical subtypes, molecular features, and treatment outcomes. Blood Cancer J. 2017, 7, 660. [Google Scholar] [CrossRef] [Green Version]
- Ishihara, S.; Okada, S.; Wakiguchi, H.; Kurashige, T.; Hirai, K.; Kawa-Ha, K. Clonal lymphoproliferation following chronic active Epstein-Barr virus infection and hypersensitivity to mosquito bites. Am. J. Hematol. 1997, 54, 276–281. [Google Scholar] [CrossRef]
- Ko, Y.H.; Park, S.; Kim, K.; Kim, S.J.; Kim, W.S. Aggressive natural killer cell leukemia: Is Epstein-Barr virus negativity an indicator of a favorable prognosis? Acta Haematol. 2008, 120, 199–206. [Google Scholar] [CrossRef] [PubMed]
- Nicolae, A.; Ganapathi, K.A.; Pham, T.H.; Xi, L.; Torres-Cabala, C.A.; Nanaji, N.M.; Zha, H.D.; Fan, Z.; Irwin, S.; Pittaluga, S.; et al. EBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic Features. Am. J. Surg. Pathol. 2017, 41, 67–74. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ryder, J.; Wang, X.; Bao, L.; Gross, S.A.; Hua, F.; Irons, R.D.; Ironsa, R. Aggressive Natural Killer Cell Leukemia: Report of a Chinese Series and Review of the Literature. Int. J. Hematol. 2007, 85, 18–25. [Google Scholar] [CrossRef]
- Nakashima, Y.; Tagawa, H.; Suzuki, R.; Karnan, S.; Karube, K.; Ohshima, K.; Muta, K.; Nawata, H.; Morishima, Y.; Nakamura, S.; et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: Different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosom. Cancer 2005, 44, 247–255. [Google Scholar] [CrossRef]
- Sumbly, V.; Vest, M.; Landry, I. Aggressive Natural Killer Cell Leukemia: A Brief Overview of Its Genomic Landscape, Histological Features, and Current Management. Cureus 2022, 14, e22537. [Google Scholar] [CrossRef] [PubMed]
- Huang, L.; Liu, D.; Wang, N.; Ling, S.; Tang, Y.; Wu, J.; Hao, L.; Luo, H.; Hu, X.; Sheng, L.; et al. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2017, 28, 172–186. [Google Scholar] [CrossRef]
IVNKTL | ENKTL | ANKL | EBV + Nodal T/NK Lymphoma | |
---|---|---|---|---|
Median Age and Sex | Adult (middle-age, around 46 yrs) M > F | Adults (elderly, around 60 yrs) M > F | Adult (mainly young adult) M = F | Adult (middle-age, often immunocompromised) M = F |
Ethnicity | Asian and Latin America | Asian | Asian | Asian |
Sites | Skin and CNS (mainly); any organ may be involved | Extranodal sites (mainly nasal region and upper aerodigestive tract), very rare primary nodal sites | BM, blood, liver, spleen; very rare nodal presentation | Commonly nodal presentation |
Nasal involvement | No | Very common | No | No |
Systemic symptoms | Protean clinical manifestations | B-symptoms | B-symptoms; often CID | B-symptoms |
Tumor mass | No | Yes, necrotic/ulcerated mass | No | Yes |
Histology | Large-sized cells within medium- to small-sized vessels | Polymorphic cells, clear cytoplasm; inflammatory background, necrosis. Angioinvasive and angiodestructive pattern. | Variable in size from normal granular lymphocytes to large, atypical cells | High-grade morphology (either polymorphic or monomorphic) |
Cell of origin | NK or cytotoxic T cells | NK > cytotoxic T cell | NK | Cytotoxic T-cell > NK |
EBV-association | Common | Common | Common | Common |
CD56 expression | Often positive | Often positive | Often positive (p16 generally positive) | Often negative |
T-cell clonality | Present in cases of T-cell origin | Present in cases of T-cell origin | No | Present in cases of T-cell origin |
Prognosis | Poor | Poor | Poor | Poor |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zanelli, M.; Parente, P.; Sanguedolce, F.; Zizzo, M.; Palicelli, A.; Bisagni, A.; Carosi, I.; Trombetta, D.; Mastracci, L.; Ricci, L.; et al. Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease. Cancers 2022, 14, 5458. https://doi.org/10.3390/cancers14215458
Zanelli M, Parente P, Sanguedolce F, Zizzo M, Palicelli A, Bisagni A, Carosi I, Trombetta D, Mastracci L, Ricci L, et al. Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease. Cancers. 2022; 14(21):5458. https://doi.org/10.3390/cancers14215458
Chicago/Turabian StyleZanelli, Magda, Paola Parente, Francesca Sanguedolce, Maurizio Zizzo, Andrea Palicelli, Alessandra Bisagni, Illuminato Carosi, Domenico Trombetta, Luca Mastracci, Linda Ricci, and et al. 2022. "Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease" Cancers 14, no. 21: 5458. https://doi.org/10.3390/cancers14215458